ASA dismisses generic drug complaint

The Advertising Standards Authority has rejected a complaint that pharmaceutical giant Bayer has been trying to disparage generic drugs and create doubts about their safety.

It said a statement in a Bayer advertorial that there were ”questions” about nifedipine’s bioequivalence were factual and in the public interest.

Nifedipine, sold under the brand names Adalat, Nifedical, and Procardia, is used for treating chest pain resulting from coronary artery spasm.

The complaint was lodged by the National Association of Pharmaceutical Manufacturers (NAPM) over an article in the March 2008 edition of the Medical Chronicle.

The advertorial said generic drugs were supposed to demonstrate bioequivalence with their brand name counterparts, and healthcare professionals therefore assumed that these products were interchangeable.

It said new studies however raised questions about the bioequivalence of generic nifedipine products, and that at least two generics tested were not able to prove bioequivalence.

Bioequivalence means that before a generic drug can be sold, the manufacturer must prove that it has the same strength as the brand name medication, and affects people the same way within the same time frame.

If a generic passes these tests, it is said to be bioequivalent to the original drug.

The NAPM complained Bayer had misrepresented facts and that the ”questions” did not apply to the South African market, as the studies related to testing in Europe on European products, which were neither
registered nor marketed in South Africa.

In response, Bayer submitted an opinion from Professor Brian Rayner of the University of Cape Town’s department of medicine, who said there was no record of anything published in the medical literature in South Africa on nifedipine.

”In the absence of local information we have to use information published elsewhere,” he wrote.

”These papers were both published in prestigious, peer-reviewed international journals.”

The advertorial, he said, was neither dishonest nor misleading.

The ASA said it was satisfied Rayner’s comments adequately supported the claims made in the advertorial. – Sapa

We make it make sense

If this story helped you navigate your world, subscribe to the M&G today for just R30 for the first three months

Subscribers get access to all our best journalism, subscriber-only newsletters, events and a weekly cryptic crossword.”

Related stories


Already a subscriber? Sign in here


Latest stories

Maxime Mokom: The Central African Republic leader on trial at...

The Central African Republic anti-Balaka leader faces charges of war crimes and crimes against humanity at the International Criminal Court

‘Break vicious cycle that deters girls in science’

Ameenah Gurib-Fakim, who served as the first female president of Mauritius from 2015- to 2018, has also had success in higher education, winning top awards in science

How sugar, tobacco or waste gases could power your next...

South Africa has the immediate technical potential to produce 3.2 billion litres of alternative aviation fuels annually

Iman Rappetti: Saving your tears doesn’t save you

We are so adept at bottling our emotions and storing them that we ignore the implications.

press releases

Loading latest Press Releases…